Placebo-controlled augmentation trials of the antioxidant NAC in schizophrenia: A review
- PMID:27490835
Placebo-controlled augmentation trials of the antioxidant NAC in schizophrenia: A review
Abstract
Background: Several studies have reported that schizophrenia is associated with mitochondrial abnormalities, glutathione deficit, and increased brain oxidative stress (free radicals). N-acetylcysteine (NAC) is a strong antioxidant with potential therapeutic benefit in schizophrenia, according to some reports. We conducted a review of the published controlled studies, with the goal of determining the efficacy profile of NAC as an adjunctive treatment for schizophrenia.
Methods: An online search was conducted for all placebo-controlled, double-blind, randomized clinical trials of NAC in schizophrenia, and a review was conducted.
Results: Two studies met the criteria for inclusion. Berk et al (2008) used NAC as an adjunctive treatment to atypical antipsychotics in subjects with chronic schizophrenia who were stable on antipsychotic medications. Treatment at 8 weeks was less efficacious than placebo, but at 24 weeks produced significant reductions vs placebo in Positive and Negative Syndrome Scale (PANSS) negative (d = 0.52), general (d = 0.46), and total (d = 0.57) scores. Farokhnia et al (2013) used NAC as an adjunctive treatment to risperidone in subjects with chronic schizophrenia who were experiencing an acute exacerbation episode. Eight weeks of treatment led to clinically significant reductions vs placebo in PANSS negative (d = 0.96), general (d = 0.59), and total (d = 0.88) scores.
Conclusions: The data suggest that adjunctive NAC may be efficacious in reducing negative and general symptoms in schizophrenia.
Similar articles
- N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi SM, Moghadam M, Gharibi F, Mirshafiee O, Akhondzadeh S.Farokhnia M, et al.Clin Neuropharmacol. 2013 Nov-Dec;36(6):185-92. doi: 10.1097/WNF.0000000000000001.Clin Neuropharmacol. 2013.PMID:24201233Clinical Trial.
- Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE.Lane HY, et al.Arch Gen Psychiatry. 2005 Nov;62(11):1196-204. doi: 10.1001/archpsyc.62.11.1196.Arch Gen Psychiatry. 2005.PMID:16275807Clinical Trial.
- Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial.Sepehrmanesh Z, Heidary M, Akasheh N, Akbari H, Heidary M.Sepehrmanesh Z, et al.Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:289-296. doi: 10.1016/j.pnpbp.2017.11.001. Epub 2017 Nov 7.Prog Neuropsychopharmacol Biol Psychiatry. 2018.PMID:29126981Clinical Trial.
- Adjunctive intranasal oxytocin for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.Zheng W, Zhu XM, Zhang QE, Yang XH, Cai DB, Li L, Li XB, Ng CH, Ungvari GS, Ning YP, Xiang YT.Zheng W, et al.Schizophr Res. 2019 Apr;206:13-20. doi: 10.1016/j.schres.2018.12.007. Epub 2018 Dec 17.Schizophr Res. 2019.PMID:30573406Review.
- Efficacy and acceptability of adjunctive n-acetylcysteine for psychotic disorders: Systematic review and meta-analysis.Zhang Q, Liu Z, Wang T, Yu M, Li X.Zhang Q, et al.Hum Psychopharmacol. 2024 Mar;39(2):e2880. doi: 10.1002/hup.2880. Epub 2023 Sep 15.Hum Psychopharmacol. 2024.PMID:37712506Review.
Cited by
- Antioxidants as a Potential Target against Inflammation and Oxidative Stress in Attention-Deficit/Hyperactivity Disorder.Alvarez-Arellano L, González-García N, Salazar-García M, Corona JC.Alvarez-Arellano L, et al.Antioxidants (Basel). 2020 Feb 21;9(2):176. doi: 10.3390/antiox9020176.Antioxidants (Basel). 2020.PMID:32098021Free PMC article.Review.
- N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence.Ooi SL, Green R, Pak SC.Ooi SL, et al.Biomed Res Int. 2018 Oct 22;2018:2469486. doi: 10.1155/2018/2469486. eCollection 2018.Biomed Res Int. 2018.PMID:30426004Free PMC article.
- Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology.Nasir M, Trujillo D, Levine J, Dwyer JB, Rupp ZW, Bloch MH.Nasir M, et al.Front Psychiatry. 2020 Nov 19;11:548505. doi: 10.3389/fpsyt.2020.548505. eCollection 2020.Front Psychiatry. 2020.PMID:33329087Free PMC article.Review.
- Autoimmune phenotypes in schizophrenia reveal novel treatment targets.Severance EG, Dickerson FB, Yolken RH.Severance EG, et al.Pharmacol Ther. 2018 Sep;189:184-198. doi: 10.1016/j.pharmthera.2018.05.005. Epub 2018 May 6.Pharmacol Ther. 2018.PMID:29742478Free PMC article.Review.
- Gastrointestinal and liver disease in patients with schizophrenia: A narrative review.Grant RK, Brindle WM, Donnelly MC, McConville PM, Stroud TG, Bandieri L, Plevris JN.Grant RK, et al.World J Gastroenterol. 2022 Oct 14;28(38):5515-5529. doi: 10.3748/wjg.v28.i38.5515.World J Gastroenterol. 2022.PMID:36304087Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous